Toronto, April 27, 2026 — The Structural Genomics Consortium (SGC) today announced the appointment of Dr. Guy Rouleau as Chair of its Board of Directors, effective July 2026.

A physician-scientist with an international reputation in neuroscience and open science, Rouleau brings decades of leadership at the intersection of discovery, translation, and system-level change. He currently serves as Director of the Montreal Neurological Institute-Hospital (The Neuro), Chair of McGill University’s Department of Neurology and Neurosurgery, and Director of Neuroscience at the McGill University Health Centre. He is also a co-founder of the Tanenbaum Open Science Institute, where he has played a defining role in establishing one of the world’s first institutional models fully committed to open science.

Over a career spanning nearly 40 years, Rouleau has led pioneering work identifying genes and molecular mechanisms underlying neurological and psychiatric disorders, including autism, ALS, epilepsy, and schizophrenia. His research has contributed to translating fundamental discoveries into clinical programs, while his broader leadership has helped shape how science is conducted, shared, and mobilized at scale. With more than 1,000 peer-reviewed publications and a track record of training over 100 scientists, he is widely recognized for both scientific excellence and community-building.

Rouleau’s appointment comes at a pivotal moment for SGC, as the organization advances to its central role in the next phase of Target 2035. This phase is defined by scaling open, high-quality data generation and enabling a shift toward computationally driven drug discovery. 

“I am incredibly excited to be able to work closely with Guy and to tap into his deep experience in open science, leadership, and community engagement,” says Aled Edwards, CEO of SGC. “It’s also fantastic that each of us shares a passion about working, sooner than later, to understand the functions of all human genes and proteins.”

“Open science is not only a principle, but a practical framework to accelerate discovery and maximize its impact,” said Rouleau. “SGC has demonstrated how collaborative, unrestricted science can transform our understanding of biology. I look forward to working with the Board and the global community to help advance this next phase.”

The SGC also extends its sincere appreciation to Dr. Anke Mueller-Fahrnow for her leadership and commitment during her tenure as the Chair of the SGC Board. Under her guidance, the organization strengthened its global partnerships and laid critical groundwork for the scale-up now underway. The SGC is also delighted that Mueller-Fahrnow has agreed to remain with SGC as the Associate Chair of the Board and as a mentor to its management team.